Neurocrine Biosciences Inc (NBIX): R&D Expense
$1.02B
Year ended 2025-12-31
$1.13B
Trailing 12 months to 2026-06-30
+29.9%
3-year compound annual growth
+29.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.02B | +38.9% | 2026-02-11, From 2025-01-01 |
| 2024-12-31 | $731.10M | +29.4% | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $565.00M | +21.8% | 2026-02-11, From 2023-01-01 |
| 2022-12-31 | $463.80M | +41.4% | 2025-02-10, From 2022-01-01 |
| 2021-12-31 | $328.10M | +19.3% | 2024-02-09, From 2021-01-01 |
| 2020-12-31 | $275.00M | n/a | 2023-02-09, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $1.02B | +38.9% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $825.00M | -9.4% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $187.52M | -3.1% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $3.13B | -31.1% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $81.49M | +3.1% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $94.77M | -4.8% |
| Novavax Inc (NVAX) | 2025-12-31 | $342.32M | -12.5% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $166.13M | -4.9% |
| Biogen Inc. (BIIB) | 2025-12-31 | $1.78B | -10.2% |
Compare NBIX, EXEL, QGEN, MRNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗